Epilepsy NZ questions PHARMAC funding change
Epilepsy patients are worried they will be worse off under Pharmac's plan to only fund one brand of Lamotrigine epilepsy medication. About 12,500 people take some type of Lamotrigine, for either epilepsy or a mental health condition like bipolar. Pharmac says a generic version called Logem is no different from other brands but patients want assurance they'll get help if they have unpleasant side affects. Charlie Dreaver reports.